NasdaqGS:ZYMEBiotechs
Why Zymeworks (ZYME) Is Up 6.7% After FDA Fast Track Win And CFO Appointment
Zymeworks Inc. recently received U.S. FDA Fast Track designation for ZW191, its folate receptor-a–targeting antibody-drug conjugate, in advanced or metastatic platinum-resistant ovarian cancer, and formally appointed veteran biopharma finance executive Kristin Stafford as Chief Financial Officer on April 1, 2026.
The combination of expedited regulatory support for ZW191 and the addition of a CFO with deep royalty and life sciences financing experience directly touches both Zymeworks’...